DUBLIN, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Davion Healthcare Plc (Nasdaq: DAVI) ('Davion' or the 'Company'), a next-generation digital healthcare company developing proprietary health monitoring technologies, today announces that it has completed the acquisition of the intellectual property relating to two medical technologies: WoundSkan, a smart wound-monitoring dressing, and the Spektra Lateral Flow Test, a rapid multi-marker screening platform..

都柏林，2026年10月26日（环球电讯社）——下一代数字医疗公司Davion Healthcare Plc（纳斯达克股票代码：DAVI）（以下简称“Davion”或“公司”），一家开发专有健康监测技术的公司，今日宣布已完成与两项医疗技术相关的知识产权收购：WoundSkan，一种智能伤口监测敷料；以及Spektra侧向层析检测，一种快速多标志物筛查平台。

The intellectual property was acquired from the four shareholders of Humaskan Ltd for a total consideration of US$25 million, comprising US$2.5 million in cash and 1,730,770 new ordinary shares in Davion, to be issued at an agreed fixed contractual value of US$13.00 per share (approximately US$22.5 million).

该知识产权从Humaskan Ltd的四位股东处收购，总对价为2,500万美元，包括250万美元现金和1,730,770股Davion新发行的普通股，按每股13.00美元的约定固定合同价值发行（约合2,250万美元）。

The number of shares is fixed and will not vary with movements in the Davion's share price..

股份数量是固定的，不会随达维翁股价的波动而变化。

The acquired technologies

所获得的技术

WoundSkan is a smart wound dressing containing a temperature sensor and a passive NFC tag. It has no battery or internal power: scanning the dressing with a smartphone powers the sensor and sends the reading to the WoundSkan app. The app records each timestamped temperature reading alongside a reading history and patient notes, so clinicians can track wound temperature, a potential early sign of infection, without removing the dressing..

WoundSkan 是一种智能伤口敷料，内置温度传感器和无源 NFC 标签。它无需电池或内部电源：使用智能手机扫描敷料即可为传感器供电，并将读数发送至 WoundSkan 应用程序。该应用程序会记录每次带时间戳的温度读数，并同步保存读数历史和患者备注，使临床医生能够在不移除敷料的情况下监测伤口温度，从而及时发现可能的感染早期迹象。

The Spektra Lateral Flow Test is a single-use screening platform. A onetime use base unit collects urine and saliva samples and takes one of ten colour-coded cartridges, each carrying antibodies for specific markers. Results are available in around two minutes and are sent to a smartphone by passive NFC..

Spektra侧流检测是一种一次性筛查平台。该一次性使用的主机单元收集尿液和唾液样本，并插入十个颜色编码的卡盒之一，每个卡盒均携带针对特定标志物的抗体。检测结果可在约两分钟内获得，并通过被动式NFC传输至智能手机。

The current cartridge range covers markers associated with certain cancers, hormonal imbalances, autoimmune conditions and neurodegenerative conditions. Although Spektra is not a diagnostic test, it is designed to identify anomalies that may warrant further clinical investigation.

目前的检测试剂盒范围涵盖与某些癌症、激素失衡、自身免疫性疾病和神经退行性疾病相关的生物标志物。尽管 Spektra 并非诊断性检测，但其设计旨在识别可能需要进一步临床检查的异常现象。

Both technologies use the battery-free, smartphone-read approach that underpins Davion's focus on health monitoring outside traditional clinical settings.

这两项技术均采用无电池、由智能手机读取的方法，这正是Davion专注于在传统临床环境之外进行健康监测的核心基础。

The acquisition includes the associated patents and patent applications, technical designs, software and algorithms, research and development data, testing information, regulatory documentation, prototypes and know-how. It also includes the rights to develop, manufacture, commercialise and license products incorporating the acquired intellectual property..

此次收购包括相关专利及专利申请、技术设计、软件与算法、研发数据、测试信息、监管文件、原型以及专有技术。此外，还包括开发、制造、商业化及许可销售 incorporating 所获知识产权的产品之权利。

The transaction covers the intellectual property and associated assets only. Davion has not acquired Humaskan Ltd as a corporate entity, nor has it taken on its employees or assumed any of its liabilities.

本次交易仅涵盖知识产权及相关资产。Davion 并未收购 Humaskan Ltd 这一法人实体，也未接收其员工或承担其任何债务。

Transaction terms

交易条款

The consideration shares will be issued after a 90-day deferral period from listing, which will be on the 20

对价股份将在上市90天的锁定期结束后发行，上市日期为20日

th

泰国

January 2027. For the following 90 days thereafter, each Seller may sell no more than 10% of Davion's five-day average daily trading volume on any trading day. The cash consideration is payable by 19 February 2027, within 120 days of the start of trading of Davion's shares on Nasdaq.

2027年1月。在此后的90天内，每位卖方在任何交易日的出售数量不得超过Davion五日平均日交易量的10%。现金对价应于2027年2月19日前支付，即Davion股票在纳斯达克开始交易后的120天内。

Strategy

策略

The acquisition is Davion's first since its direct listing on the Nasdaq Global Market on 22 October 2026. It follows the Group's adoption of a direct commercialisation strategy in June 2026. Davion's growth strategy combines the commercialisation of its proprietary technologies, including BreastCheck, with acquisitions across medical devices, healthcare services, medical distribution, healthcare technology and diagnostics..

此次收购是Davion自2026年10月22日在纳斯达克全球市场直接上市以来的首次收购。此前，集团于2026年6月采取了直接商业化战略。Davion的增长战略将其专有技术（包括BreastCheck）的商业化与在医疗器械、医疗服务、医疗分销、医疗技术和诊断领域的收购相结合。

To support its acquisition programme, Davion has established Davion Healthcare Finance Ltd and launched a £30 million five-year senior secured bond. The Group's acquisition programme is overseen by its Operational Directorate, led by Chief Executive Officer Glenn Williams.

为支持其收购计划，Davion 成立了 Davion Healthcare Finance Ltd，并发行了为期五年、金额达 3,000 万英镑的高级担保债券。该集团的收购计划由其运营董事会负责监督，该董事会由首席执行官格伦·威廉姆斯（Glenn Williams）领导。

Glenn Williams, Chief Executive Officer of Davion Healthcare, commented:

Davion Healthcare 首席执行官格伦·威廉姆斯表示：

'This acquisition is an important step in our plans to build a substantial international healthcare business, combining the development of our existing portfolio with the acquisition of complementary technologies.

“此次收购是我们构建庞大国际医疗健康业务计划中的重要一步，将我们现有产品组合的开发与互补技术的收购相结合。”

'WoundSkan and Spektra are both innovative, practical technologies with considerable commercial potential. WoundSkan builds on our existing expertise in temperature-based monitoring, offering a way to assess wounds without removing dressings, while Spektra provides rapid screening for multiple conditions from a single sample.

WoundSkan 和 Spektra 均为具有显著商业潜力的创新实用技术。WoundSkan 依托我们在基于温度的监测领域已有的专业知识，提供了一种无需移除敷料即可评估伤口的方法；而 Spektra 则能够通过单个样本对多种疾病进行快速筛查。

Both have applications across a range of healthcare settings..

两者在多种医疗场景中均有应用。

'Following our recent Nasdaq listing, we are well positioned to accelerate the development and commercialisation of these technologies, while continuing to pursue further acquisition opportunities.'

“在近期于纳斯达克上市后，我们已具备有利条件，可加速这些技术的开发与商业化进程，同时继续寻求更多的收购机会。”

Media Enquiries

媒体问询

Rosewood Communications

罗斯伍德通讯

+44 (0) 20 7653 8702

+44 (0) 20 7653 8702

davion@rosewoodpr.co.uk

davion@rosewoodpr.co.uk

Investor Relations Inquiries

投资者关系咨询

Mark Komonoski

马克·科莫诺斯基

Partner

合作伙伴

Integrous Communications

诚信通讯

Toll Free: 877-255-8483

免费电话：877-255-8483

Mobile: 403-470-8384

手机：403-470-8384

About Davion Healthcare Plc

关于 Davion Healthcare Plc

Davion Healthcare Plc is a next-generation digital healthcare company developing proprietary, non-invasive health monitoring technologies designed to support the early identification of medical anomalies outside traditional clinical environments.

Davion Healthcare Plc 是一家下一代数字医疗公司，正在开发专有的非侵入式健康监测技术，旨在支持在传统临床环境之外早期识别医学异常。

The Company’s flagship product, BreastCheck, is an FDA-registered at-home breast health screening test designed to identify potential abnormalities through changes in breast temperature. Davion’s broader portfolio includes technologies addressing circulation and foot health, testicular health, skin anomalies, wound monitoring, blood pressure and other areas of preventive healthcare..

公司的旗舰产品BreastCheck是一款已在FDA注册的居家乳腺健康筛查测试，旨在通过监测乳房温度变化来识别潜在异常。Davion更广泛的产品组合包括针对循环系统与足部健康、睾丸健康、皮肤异常、伤口监测、血压以及其他预防性保健领域的技术。

Davion’s growth strategy combines the development and commercialisation of its proprietary technologies with complementary acquisitions intended to expand the Group’s product portfolio and commercial, manufacturing and distribution capabilities.

Davion 的增长战略结合了其专有技术的开发与商业化，以及旨在扩大集团产品组合和商业、制造和分销能力的互补性收购。

Further information is available at

更多信息请访问

www.davionhealthcare.com

www.davionhealthcare.com

.

。

Forward-Looking Statements

前瞻性陈述

This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, those identified by words such as “believes,” “will,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions..

本公告包含1995年美国《私人证券诉讼改革法》“安全港”条款所定义的前瞻性陈述。此类陈述包括但不限于使用“相信”、“将”、“预期”、“预计”、“估计”、“打算”、“计划”、“目标”、“预测”等词语及类似表述所识别的陈述。

The statements in this release are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in these forward-looking statements.

本新闻稿中的陈述基于公司管理层当前的信念和预期，并受重大风险和不确定性的影响。实际结果可能与这些前瞻性陈述中所述的结果存在差异。

Numerous factors could cause or contribute to such differences, including, but not limited to, the results of product evaluations, studies, regulatory reviews and commercial adoption and/or other studies, clinical trials, the challenges inherent in new product development initiatives, the impact of any competitive products, the Company’s ability to license and protect its intellectual property, its ability to raise additional capital in the future, changes in government policy and/or regulation, potential litigation by or against the Company, any governmental review of its products or practices, and other risks discussed from time to time in the Company’s filings with the Securities and Exchange Commission..

众多因素可能导致或促成此类差异，包括但不限于：产品评估结果、研究、监管审查及商业化采纳情况和/或其他研究、临床试验、新产品开发举措所固有的挑战、任何竞争性产品的冲击、公司许可和保护其知识产权的能力、未来筹集额外资本的能力、政府政策和/或法规的变化、针对公司或由公司发起的潜在诉讼、政府对其产品或实践的任何审查，以及公司在向美国证券交易委员会提交的文件中不时讨论的其他风险。

The Company undertakes no obligation to update any forward-looking statements, or any information contained in this press release or in other public disclosures, at any time, except as required by applicable law.

除非适用法律另有要求，公司不承担任何义务在任何时候更新任何前瞻性陈述或本新闻稿及其他公开披露中包含的任何信息。

The investing public is reminded that only announcements or information about Davion Healthcare Plc disseminated by the Company and bearing its name are considered official.

提醒广大投资者，只有由Davion Healthcare Plc公司发布并署名的公告或信息才被视为官方信息。